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F O R U M
Vaccine- induced immune thrombotic thrombocytopenia 
(VITT): Update on diagnosis and management considering 
different resources
Abstract
Vaccine- induced immune thrombotic thrombocytopenia 
(VITT) is a rare but severe immunological reaction to the 
non- replicable adenoviral vector- based COVID- 19 vac-
cines. Extreme activation of platelets and the coagulation 
system leads to a high risk of death from venous or arte-
rial thrombosis or secondary hemorrhage. Public and cli-
nician awareness has reduced mortality of VITT by nearly 
90%. The World Health Organization provided a guideline 
in July 2021 on diagnosis and management of VITT (also 
called thrombosis with thrombocytopenia syndrome, or 
TTS). Since July 2021, new, clinically relevant information 
has become available. This update has been summarized 
by the authors in an informal process with recommenda-
tions for low resource environments. We provide new 
available evidence on VITT to empower clinicians to rec-
ognize VITT early, then effectively diagnose and treat the 
disorder to reduce morbidity and mortality. We strongly 
encourage production of clear management pathways for 
primary care settings and hospital settings.
1  |  BACKGROUND
Vaccine- induced immune thrombotic thrombocytopenia (VITT) is 
a rare but severe immunological reaction to the non- replicable ad-
enoviral vector- based COVID- 19 vaccines. Extreme activation of 
platelets and the coagulation system leads to a high risk of death 
from venous or arterial thrombosis or secondary hemorrhage. Public 
and clinician awareness has reduced mortality of VITT from about 
50%, in the first case series reported in April 2021 to 22% by June 
2021 in the UK and more recently to about 5% observed in Australia, 
where the vaccination campaign was accompanied by a widespread 
educational program on VITT (https://www.tga.gov.au/perio dic/
covid - 19- vacci ne- weekl y- safet y- repor t- 23- 09- 2021). This indicates 
that education of the public and health- care workers can substan-
tially lower the burden of the adverse vaccination effect and may 
support acceptance of the vaccination campaign. The planned roll-
out of at least 1 billion doses of the ChAdOx1 COVID- 19 vaccine 
(AstraZeneca) starting in October 2021 to low- and middle- income 
countries requires urgent availability of educational material.
The World Health Organization (WHO) has developed a com-
prehensive document guiding diagnosis and management of throm-
bosis with thrombocytopenia syndrome (TTS) following vaccination 
to prevent coronavirus disease (COVID- 19); interim guidance 19 July 
2021 (https://apps.who.int/iris/bitst ream/handl e/10665/ 34299 9/
WHO- 2019- nCoV- TTS- 2021.1- eng.pdf). However, since its publica-
tion in July, additional new information that is relevant for patient 
management has become available. To bridge the time required for 
updating the WHO guidelines, international authors summarized the 
most up- to- date information in October 2021. The summary was 
then reviewed by three experts in the field.
We distinguish VITT, which is a unique and specific syndrome, 
from TTS, which may occur in other disorders such as heparin- 
induced thrombocytopenia (HIT), severe antiphospholipid syndrome 
(APS), cancer- associated disseminated intravascular coagulopathy, 
and thrombotic thrombocytopenic purpura (TTP). VITT most com-
monly presents with cerebral venous sinus thrombosis, but splanch-
nic vein thrombosis, deep vein thrombosis and pulmonary embolism 
(venous thromboembolism [VTE]), and arterial thrombosis are also 
common, as is involvement of multiple vascular beds.
2  |  GOAL S
• Empower clinicians to recognize VITT early, then effectively diag-
nose and treat the disorder to reduce morbidity and mortality.
• Empower the public to be aware of VITT without causing undue 
alarm or overburdening the health- care system.
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• Produce clear management pathways for: primary care settings 
and hospital settings, with recommendations for low- resource 
environments.
• Inform on the existence of treatment.
• Emphasize the real frequency of VITT and the overall benefit of 
vaccination.
3  |  FUNDAMENTAL S OF DIAGNOSIS AND 
L ABOR ATORY TESTING
• VITT occurs after vaccination with non- replicant adenovirus 
vector- based vaccines (ChAdOx1, AstraZeneca/COVISHIELD; 
Ad26COV2.S, Janssen, Johnson & Johnson).
• Symptoms suggestive of VITT: persistent and severe headache, 
occurring with a time delay following vaccination (discussed 
subsequently), with red flags, such as progressive worsening 
and resistance to symptomatic treatment; persistent and severe 
abdominal or back pain; focal neurological symptoms (including 
blurred or double vision); shortness of breath; persistent and se-
vere chest pain; swelling and redness of a limb; or pallor and cold-
ness of a limb.
• Symptoms begin 5 or more days after vaccination, and typical pre-
sentations do not occur beyond 30 days except in some patients 
with isolated deep vein thromboses and pulmonary emboli, where 
the disease may remain subclinical for longer.
• Patients may have multiple organ thrombosis, and in VITT pa-
tients with new symptoms or symptoms from different organs or 
systems, additional thromboses must be ruled out.
• Platelet count and D- dimer are the most important screening lab-
oratory tests.
• Two scenarios to consider after the platelet count result:
a. VITT UNLIKELY: Persistently normal platelet count (≥150 000/
µL). This does not rule out thrombosis due to other causes. 
Clinicians should work up alternative diagnoses, including non- 
VITT thrombosis. If no alternative diagnosis is found, patients 
should be encouraged to seek care immediately (and have a 
repeat platelet count) if symptoms worsen. Note: Especially in 
patients with a high platelet count before onset of VITT even 
a substantial decrease in platelet count may not cause platelet 
count numbers <150 000/µL, or it may take longer until the 
platelet count decreases to <150 000/µL. If symptoms clini-
cally persist, a repeat blood cell count should be performed. 
Note: if D- dimer is less than 2000 fibrinogen equivalent units 
(FEU; or four times the upper limit of normal), VITT is unlikely.
b. VITT LIKELY: New onset platelet count <150 000/µL (check 
whether patient has previous platelet counts available), 
5– 30 days post adenoviral vaccination. If D- dimer is elevated 
>4000 FEU (and more than eight times the upper limit of 
normal) and is not better explained by another disorder (e.g., 
COVID- 19 infection), VITT is likely, even if the patient does 
not have confirmed thrombosis. If D- dimer is not available, see 
below.
• What to do if no D- dimer assay is available:
a. Refer to the histogram of the automated particle counter; it 
will show a broadened curve not reaching baseline and not 
the typical smooth semi- logarithmic appearance. In addition, a 
blood film should be performed. In VITT, it will typically show 
multiple small platelet aggregates of 5– 10 platelets. These 
small aggregates are not present in immune thrombocytope-
nic purpura patients (Figure 1).
4  |  ADVANCED L ABOR ATORY TESTING
• Standard laboratory testing. 
a. If available, an international normalized ratio/prothrombin 
time (INR/PT), activated partial thromboplastin time (APTT), 
and fibrinogen level can confirm and serially monitor for dis-
seminated intravascular coagulopathy (DIC), an important 
feature of VITT. Take blood sample before anticoagulation is 
started to avoid interference of anticoagulants with test re-
sults. Note that INR/PT and APTT is not consistently abnor-
mal in all patients. Note also that patients on argatroban may 
have falsely reduced fibrinogen levels in vitro when the Clauss 
or PT- derived methods are used.
b. If available and if splanchnic vein thrombosis is suspected, a 
bilirubin, aspartate transaminase, alanine transaminase, and 
alkaline phosphatase can be useful to understand the extent 
and impact of the thrombus.
• Antibody testing. 
a. The diagnosis of VITT can be confirmed with ELISA plate- 
based platelet factor 4 (PF4)/heparin (polyanion) antibody 
tests, which will demonstrate anti- PF4 antibodies. No PF4/
heparin ELISA recognizes all VITT patients (for special-
ists: sensitivity of different commercial tests see 10.1111/
jth.15362). A negative test makes VITT unlikely but does not 
necessarily exclude the diagnosis. Antibodies persist for at 
least 4 weeks (and usually much longer) in all patients, and 
(unlike platelet activation assays) ELISA reactivity is not 
inhibited by treatment with high- dose intravenous immu-
noglobulin (IVIG); thus, diagnosis can be confirmed retro-
spectively using either acute serum/plasma (if available) or 
usually serum/plasma obtained several weeks or months 
after initial presentation.
b. Rapid tests (including point of care tests using lateral flow 
technology) do not reliably detect these antibodies and should 
not be used.
c. Consideration should be given to setting up regional re-
ferral centers that are capable of performing high sen-
sitivity anti- PF4 antibody testing by validated ELISA 
techniques. Antibodies are stable in whole blood or 
serum shipped (at room temperature) to referral centers 
for at least 3 days.
d. If no PF4 test is available, store serum sample at −20°C for 
later testing. Valid data on the prevalence of VITT in different 
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ethnicities are urgently needed and stored samples can be 
used for this purpose.
• Functional assays. 
a. Consideration should be given to setting up regional referral 
centers that are capable of performing functional assays of 
platelet activation to confirm the diagnosis of VITT and differ-
entiate it from HIT. Blood samples for functional tests should 
be obtained before treatment with IVIG is started (IVIG inhib-
its functional assays).
5  |  FUNDAMENTAL S OF IMAGING
• Cerebral venous sinus thrombosis (CVST) is potentially the most 
serious and life- threatening form of VITT. Unenhanced computed 
tomography (CT) of the brain is a reasonable first diagnostic im-
aging test for suspected CVST, as it can rule out alternative di-
agnoses (including intracranial hemorrhage) that have similar 
symptoms and may show indirect signs. However, it is not sen-
sitive enough to rule out CVST. In case of suspicion of VITT with 
CVST, both parenchymal and vascular imaging are required, either 
with an urgent non- contrast CT head and a CT venogram, or with 
an urgent magnetic resonance (MR) head and a contrast enhanced 
MR venogram.
In centers where imaging is not readily available and there is 
a high clinical suspicion of VITT, appropriate empiric treatment 
should be initiated while imaging is arranged; therapeutic dose 
anticoagulation is justified by typical symptoms (e.g., persistent 
and severe headache with red flags, such as progressive worsening 
and resistance to symptomatic treatment, and no better explana-
tion for the patient’s thrombocytopenia and elevated D- dimer), 
and objective confirmation of CVST can be done after starting 
anticoagulation.
In case of uncertainty of the diagnosis, the unlikely, possible, 
probable, definite criteria (Table 1) have been shown to be clinically 
easy to apply.
F I G U R E  1  May- Grünwald stained blood smear analysis (A- J, microscopic analysis) and platelet histograms (E,F) from two patients 
with reduced platelet counts (K) suggestive of vaccine- induced immune thrombotic thrombocytopenia (VITT). Blood counts revealed 
thrombocytopenia in both patients. In routine blood smears aggregated (A- D; dotted arrows, platelet aggregates) and enlarged platelets 
(C- D, solid arrows; May- Grünwald Giemsa stain; scale bar 50 μm) were readily detectable upon hospitalization. Increased platelet volume 
was confirmed by impedance measurement (E,F; PLT histograms; LD = lower discriminator, UD = upper discriminator). The patients received 
intravenous argatroban and 2g/kg immunoglobulin on days 3 and 4 (patient 1) or on day 1 and 2 (patient 2) post hospitalization. Within 6– 9 
days, the platelet changes observed upon hospitalization normalized (G- K). Obtained from: Zimmermann S, Federbusch M, Isermann B, Kohli 
S. Vaccine induced thrombotic thrombocytopenia: insights from blood smear. Thromb Haemost. 2021 Oct 28. doi: 10.1055/a- 1681- 7286. 
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6  |  FUNDAMENTAL S OF MANAGEMENT
• Management pathways should be put in place before mass vacci-
nation campaigns begin, and should be tailored to local diagnostic 
and therapeutic capacity. There should be a very clearly labelled 
flowchart in the hospital emergency department. The neurology 
and hematology teams should also be available to assist as needed.
• Patients can deteriorate very quickly and treatment should not be 
delayed.
• Patients with likely or confirmed VITT should ideally be treated in the 
inpatient setting, where they can be monitored for complications and 
disease progression until they considerably improve clinically.
• Anticoagulation is the first pillar of treatment in VITT. It should 
be started in all patients with probable or definite VITT. Safe anti-
coagulants include oral and parenteral direct thrombin inhibitors 
(DTI), oral factor Xa inhibitors, and fondaparinux. They should 
be dosed similarly to the dose used to treat uncomplicated VTE. 
Renal and hepatic impairment, the ability to monitor parenteral 
DTI, as well as the ability to take oral medication, may influence 
dosing and choice of agent.
• A minority of VITT patients (number is likely <5%) present with-
out overt thrombosis. Many of these patients have a presenting 
symptom of severe headache that started with a delay of 5 days 
after vaccination with negative neuroimaging studies, raising the 
possibility of microvascular thrombosis that has not progressed to 
macrovascular CVST. Despite absence of documented thrombo-
sis, these individuals are still at high risk of thrombosis (similar to 
HIT without thrombosis), and should be managed no differently 
from patients with VITT who have overt thrombosis. In these 
cases, repeat imaging should be performed about 1 week after 
start of anticoagulation to confirm absence of thrombosis (rele-
vant for duration of anticoagulation).
• Heparin does not appear to be dangerous in the vast majority of 
VITT patients. Heparin inhibits platelet activation in VITT by com-
petitive binding in vitro. About 5% of VITT patients have antibod-
ies that cross- react with PF4/heparin complexes.The hesitancy 
to use heparin likely stems from the fact that rapid exclusion of 
heparin cross- reactivity is usually not possible. (Waiting for func-
tional testing can cause unacceptable treatment delays.) For this 
reason, it is recommended to use a non- heparin anticoagulant for 
initial treatment. However, if non- heparin anticoagulants are not 
available, heparin should be used to treat probable and definite 
VITT. Delaying anticoagulation in this intensely prothrombotic 
condition is much more dangerous than giving heparin.
• Dampening of the immune response is the second pillar of VITT 
treatment. This is best done with administration of high- dose 
IVIG, which helps to inhibit platelet activation and downregu-
lates anti- PF4 antibody. An initial dose of 1 g/kg of actual body 
weight should be given. For treatment of CVST and splanch-
nic thrombosis, a second dose of 1 g/kg of actual body weight 
should be given on the next day. For all other patients, the sec-
ond dose can be reserved for cases in which the platelet count 
and D- dimer fail to respond (generally by day 3 or 4), or the 
patient worsens clinically.
• If IVIG is not available, steroids (e.g., prednisone 1– 2 mg/kg/day; 
or dexamethasone 40 mg/day for 4 days) are a reasonable choice.
TA B L E  1  Modified from Pavord et al.*
Case definition criteria
Likelihood of VITT Clinical and laboratory features Recommended management
Onset of symptoms 5– 30 days post COVID- 19 vaccine (or up to 42 days if isolated 
DVT/PE)
Documented thrombosis or severe and persistent headache
Thrombocytopenia (platelet count <150 000/µL)
D- dimer >4000 FEU (and >8× ULN)
Positive anti- PF4/heparin IgG ELISA assay
Definite VITT Meets all five criteria Anticoagulation, IVIG
Probable VITT D- dimer > 4000 FEU (and >8x ULN), but one criteria not fulfilled (timing, thrombosis, 
thrombocytopenia, anti- PF4/heparin antibodies)
or D- dimer unknown or 2000– 4000 FEU (4– 8 × ULN) with all other criteria present
Anticoagulation, IVIG
Possible VITT D- dimer unknown or 2000– 4000 FEU (4– 8 × ULN) with one other criteria not fulfilled
or two criteria not fulfilled (timing, thrombosis, thrombocytopenia, anti- PF4/heparin 
antibodies)
Anticoagulation, close clinical 
monitoring,
Unlikely Platelet count <150 000/µL without thromboses, D- dimer <2000 FEU (<4× ULN), 
regardless of anti- PF4/heparin antibody result, and/or alternative diagnosis more 
likely




Abbreviations: DVT, deep vein thrombosis; FEU, fibrinogen equivalent units; ITP, immune thrombocytopenic purpura; IVIG, intravenous 
immunoglobulin; PE, pulmonary embolism; PF4, platelet factor 4; ULN, upper limit of normal; VITT, vaccine- induced immune thrombotic 
thrombocytopenia.
*Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, Rampotas A, Ambler G, Makris M. Clinical features of vaccine- induced immune 
thrombocytopenia and thrombosis. N Engl J Med. 2021 Aug 11. 10.1056/NEJMo a2109908. Online ahead of print.
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• In very severe cases with platelet counts <30 000/µL and severe 
thrombosis, plasma exchange seems to improve outcome based 
on small case series.
• Thrombocytopenia is not a contraindication to therapeutic dose 
anticoagulation in VITT. In fact, individuals with the lowest plate-
let counts may well be at highest risk of thrombosis. It is critical 
to begin IVIG in patients with VITT and profound thrombocyto-
penia, as raising the platelet count in concert with anticoagulation 
should mitigate bleeding risk.
• The duration of anticoagulation is still unclear. In general, treat-
ment must continue as long as the platelet count is low, and 
the D- dimer is elevated. The optimal duration is likely similar to 
non- VITT thrombosis (e.g., 3– 6 months for venous thrombosis). 
Extended duration treatment can be challenging in areas with lim-
ited access to non- heparin anticoagulants.
• In a small subset of VITT patients, platelet activating anti- PF4 
antibodies persist for at least 5 months. Especially in patients 
who show persistently reduced platelet count numbers, D- dimer 
should be retested after stop of anticoagulation. An increase in 
D- dimer without other explanation indicates ongoing clotting ac-
tivation and anticoagulation should be resumed.
7  |  THER APIES TO AVOID
• Vitamin K antagonists must be avoided in acute VITT. They 
can cause protein C deficiency, and if the patient is already in a 
strongly hypercoagulable state (such as in VITT, HIT, malignancy, 
shock liver), they increase the risk for microcirculatory thrombo-
sis. Vitamin K antagonists may be considered in the subacute pe-
riod of VITT, that is, when the platelet count has normalized and 
remains stable for at least a week.
• Aspirin must be avoided in acute VITT. Aspirin does not prevent 
or treat VITT. It does not prevent platelet activation in this con-
dition and could increase the risk of bleeding. In patients with 
anti- platelet drug medication before onset of VITT, continuation 
should be discussed with the cardiologist balancing bleeding risk 
and underlying indication.
• It is not clear if platelet transfusions worsen thrombosis in VITT. 
Platelet transfusion should only be considered for patients present-
ing with a life- threatening bleed, or requiring urgent major surgery 
and should ideally be given under the guidance of a hematologist.
8  |  SPECIAL CONSIDER ATIONS AROUND 
PREGNANCY AND L AC TATION
• Pregnant and lactating patients can safely have CT scans and 
MRIs to diagnose possible CVST. These imaging modalities are 
also important to rule out other causes of severe and persistent 
headache, including intracranial hemorrhage or space- occupying 
lesions. Consultation with radiologists should be sought to ensure 
appropriate shielding is used if CT scanning is done. Appropriate 
imaging should not be withheld in probable or definite VITT.
• In pregnant and lactating patients with probable or definite VITT, 
anticoagulation should not be withheld. The only suitable options 
for anticoagulation are heparin/low molecular weight heparin; or 
if available danaparoid or fondaparinux (very limited data). Direct 
oral factor Xa inhibitors are not recommended. IVIG is safe in 
pregnant and lactating patients. IVIG should not be withheld in 
probable or definite VITT.
• If IVIG is not available, steroids should be given in probable or defi-
nite VITT. Uncontrolled VITT is far more harmful to maternal and 
fetal health than any potential risks of steroid use. Short courses of 
steroids are safe in pregnant and lactating patients. Obstetricians 
and maternal fetal medicine specialists should be involved in pa-
tient management, particularly to advise on the risks and benefits 
of corticosteroid use, especially during the first trimester.
9  |  STR ATEGIES AROUND VACCINATION
• Dosing interval for ChAdOx1 nCov- 19 vaccine.
a. The recommended interval of 3 months should be maintained, 
as this will reduce the risk that an individual who developed 
platelet- activating anti- PF4 antibodies after first vaccination 
will receive the second vaccination shot while these antibod-
ies are still circulating. We know from HIT that use of hep-
arin in an individual who has circulating heparin- dependent 
platelet activating antibodies can induce acute abrupt onset 
HIT. (Background information: In HIT for one individual with 
clinically evident HIT, there are about ten asymptomatic in-
dividuals despite circulating platelet activating antibodies. 
However, these asymptomatic individuals can experience 
“clinical breakthrough,” when heparin is given.)
• Second vaccination in patients with confirmed VITT.
a. Second dose mRNA vaccine is safe in patients with a history 
of VITT. The second (and subsequent) vaccination in patients 
should ideally be with an mRNA vaccine, regardless of whether 
VITT antibodies are still circulating or not.
b. Likely also inactivated virus vaccines are safe but no data are 
available yet.
c. We believe a second vaccination with the ChAdOx1 nCov- 
19 vaccine would be tolerated by most of these patients. An 
analogy would be HIT, in which re- exposure to heparin does 
not cause problems in most patients. Moreover, though there 
are reported cases of VITT associated with a second dose 
ChAdOx1 nCov- 1, the vast majority have been found to be 
anti- PF4 antibody negative. VITT appears to be almost exclu-
sively a “first dose problem.”
9.1  |  Background information
If VITT patients must be re- exposed to the ChAdOx1 nCov- 19 vac-
cine, due to resource/availability/access issues, all efforts should be 
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made to collect information on their clinical course. When robust 
evidence becomes available that the ChAdOx1 nCov- 19 vaccine 
can be safely used a second time in VITT patients without adverse 
effects, this will make management of those patients in countries 
without ready access to non- adenoviral vector vaccines much easier.
We strongly support full vaccination— with a complete series 
of— in all patients globally, including heterologous prime- boost vac-
cination (“mix and match” vaccines) in VITT patients if they have ac-
cess to mRNA vaccines. We appreciate that global vaccine inequity 
is a major concern, and not all global citizens have the same access 
to vaccines, and to vaccine choice. The rise of highly transmissible 
COVID- 19 variants is most concerning in areas with low vaccine 
coverage. Therefore, we do not support a strategy of incomplete 
vaccination in individuals with a history of VITT, as this leaves them 
and their fellow citizens who are immunocompromised and/or are 
unable to receive the vaccine for whatever reason, susceptible to 
COVID- 19 complications. All efforts should be made to get these 
individuals fully vaccinated and optimally protected from COVID- 19.
10  |  SURVEILL ANCE AND SUPPORT
• Though VITT is a rare vaccine- related adverse event, cases 
will certainly present in any setting where adenoviral vector 
COVID- 19 vaccines are administered. This condition causes 
considerable morbidity and mortality, so clinicians must be pre-
pared to effectively diagnose and treat it. Moreover, effective 
surveillance systems must be in place to facilitate case finding, 
and effective reporting structures must be in place to facilitate 
thorough data collection and rapid clinical support. Clinicians (and 
patients) should be encouraged to report cases, in the spirit of 
transparency and vaccine safety.
• We recommend organized national/international help centers 
for VITT, providing round- the- clock support and telemedicine 
functionality.
Selected relevant VITT references published after June 2021.
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